The invention features methods of identifying a subject as being likely to have a positive therapeutic response to a psychedelic agent. Methods of the invention also include administering a psychedelic agent to a subject (e.g., a subject that has been identified as likely to respond positively thereto) to improve mental or physical well-being in the subject (e.g., by treating stress, anxiety, addiction, depression, compulsive behavior, by promoting weight loss, by improving mood, by treating or preventing a condition (e.g., psychological disorder), or by enhancing performance).

The invention features methods of identifying a subject as being likely to have a positive therapeutic response to a psychedelic agent. Methods of the invention also include administering a psychedelic agent to a subject (e.g., a subject that has been identified as likely to respond positively thereto) to improve mental or physical well-being in the subject (e.g., by treating stress, anxiety, addiction, depression, compulsive behavior, by promoting weight loss, by improving mood, by treating or preventing a condition (e.g., psychological disorder), or by enhancing performance).

When water pressure transfer of decorative layer or layers is carried out on an article using a water pressure transfer sheet 202 having a non-extensible decorative layer 22 providing hologram function and an extensible decorative layer 24 of print pattern sequentially from a top of said water pressure transfer sheet, a plurality of preformed cracks 26 are formed in said non-extensible decorative layer 22 of said water pressure transfer sheet 201 before said water pressure transfer sheet 202 lands on water, then an activating agent for wetting and activating said extensible decorative layer 24 is applied, and thereafter said water pressure transfer sheet lands on the water whereby water pressure transfer is carried out having high profile followability.

A packaging system for emergency access to cardiac medications, where the patient has convenient and safe access to aspirin and nitroglycerin for immediate use at the onset of cardiac chest pain or suspected cardiac chest pain.

A packaging system for emergency access to cardiac medications, where the patient has convenient and safe access to aspirin and nitroglycerin for immediate use at the onset of cardiac chest pain or suspected cardiac chest pain.

A packaging system for emergency access to cardiac medications, where the patient has convenient and safe access to aspirin and nitroglycerin for immediate use at the onset of cardiac chest pain or suspected cardiac chest pain.

The present invention relates to Coix seed oil extracted from Semen Coicis, pharmaceutical preparations thereof, and the use thereof in the treatment of tumors. Specifically, the Coix seed oil contains 5 diglyceride and 11 triglyceride ingredients in the following mass percentages: 1,3-diolein 0.40-0.58%, 1-linolein-3-olein 0.91-1.31%, 1,2-diolein 0.24-0.35%, 1-olein-2-linolein 0.66-0.95%, 1,2-dilinolein 0.33-0.47%, trilinolein 4.87-6.99%, 1-olein-2,3-dilinolein 13.00-18.69%, 1-palmitin-2,3-dilinolein 5.25-7.54%, 1,3-diolein-2-linolein 13.23-19.02%, 1-palmitin-2-linolein-3-olein 10.26-14.75%, 1,3-dipalmitin-2-linolein 2.28-3.28%, triolein 14.44-20.76%, 1-palmitin-2,3-diolein 8.06-11.58%, 1-olein-2-linolein-3-stearin 1.37-1.97%, 1,3-dipalmitin-2-olein 1.52-2.19% and 1,2-diolein-3-stearin 1.29-1.86%.

The present invention relates to Coix seed oil extracted from Semen Coicis, pharmaceutical preparations thereof, and the use thereof in the treatment of tumors. Specifically, the Coix seed oil contains 5 diglyceride and 11 triglyceride ingredients in the following mass percentages: 1,3-diolein 0.40-0.58%, 1-linolein-3-olein 0.91-1.31%, 1,2-diolein 0.24-0.35%, 1-olein-2-linolein 0.66-0.95%, 1,2-dilinolein 0.33-0.47%, trilinolein 4.87-6.99%, 1-olein-2,3-dilinolein 13.00-18.69%, 1-palmitin-2,3-dilinolein 5.25-7.54%, 1,3-diolein-2-linolein 13.23-19.02%, 1-palmitin-2-linolein-3-olein 10.26-14.75%, 1,3-dipalmitin-2-linolein 2.28-3.28%, triolein 14.44-20.76%, 1-palmitin-2,3-diolein 8.06-11.58%, 1-olein-2-linolein-3-stearin 1.37-1.97%, 1,3-dipalmitin-2-olein 1.52-2.19% and 1,2-diolein-3-stearin 1.29-1.86%.

The invention provides novel analogues of enacyloxin Ha and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii. Compounds in accordance with the invention include those of formula (A), and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs: In formula (A): X is 0 or NR.sup.x (where R* is either H or C.sub.1-3 alkyl, e.g. CH.sub.3); R.sup.1 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R.sup.1 is an optionally substituted straight-chained or branched C.sub.1-6 alkyl group (e.g. C.sub.1-3 alkyl group); R.sup.2 is H, F, Cl, Br, I or CH.sub.3; R.sup.3 is H or OH; R.sup.8 is a straight-chained or branched C.sub.1-8 alkyl group (e.g. a C.sub.1-6 alkyl group); Y is one of the following groups: (wherein each * denotes the point of attachment of the group to the remainder of the molecule; R.sup.9 is H, F, Cl, Br or I; R.sup.4 and R.sup.5 are independently selected from H and OH, or R.sup.4 and R.sup.5 together are =0, preferably R.sup.4 is H and R.sup.5 is OH; R.sup.6 is H, F, Cl, Br, I or CH.sub.3; R.sup.7 is H and R.sup.7 is OH, or R.sup.7 and R.sup.7 together are =0, preferably R7 is H and R7 is OH); and each independently represents an optional bond (i.e. each of C.sub.2-C.sub.3, C.sub.4-C.sub.5, C.sub.6-C.sub.7, C.sub.8-C.sub.9 and C.sub.10-C.sub.11 are independently either CC (single) or CC (double) bonds).

The invention provides novel analogues of enacyloxin Ha and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii. Compounds in accordance with the invention include those of formula (A), and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs: In formula (A): X is 0 or NR.sup.x (where R* is either H or C.sub.1-3 alkyl, e.g. CH.sub.3); R.sup.1 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R.sup.1 is an optionally substituted straight-chained or branched C.sub.1-6 alkyl group (e.g. C.sub.1-3 alkyl group); R.sup.2 is H, F, Cl, Br, I or CH.sub.3; R.sup.3 is H or OH; R.sup.8 is a straight-chained or branched C.sub.1-8 alkyl group (e.g. a C.sub.1-6 alkyl group); Y is one of the following groups: (wherein each * denotes the point of attachment of the group to the remainder of the molecule; R.sup.9 is H, F, Cl, Br or I; R.sup.4 and R.sup.5 are independently selected from H and OH, or R.sup.4 and R.sup.5 together are =0, preferably R.sup.4 is H and R.sup.5 is OH; R.sup.6 is H, F, Cl, Br, I or CH.sub.3; R.sup.7 is H and R.sup.7 is OH, or R.sup.7 and R.sup.7 together are =0, preferably R7 is H and R7 is OH); and each independently represents an optional bond (i.e. each of C.sub.2-C.sub.3, C.sub.4-C.sub.5, C.sub.6-C.sub.7, C.sub.8-C.sub.9 and C.sub.10-C.sub.11 are independently either CC (single) or CC (double) bonds).